Amycretin Research: What 20 Studies Show (2026) | RetatrutideCompare

Amycretin — 20 studies indexed on PubMed. Single peptide that activates both the amylin and GLP-1 receptor families. Half-life: ~7 days (subcutaneous formulation). FDA status: Investigational (Phase 2 oral, Phase 1b subcutaneous).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Amycretin?

There are approximately 20 studies indexed on PubMed that mention Amycretin (NN1213, Amylin/GLP-1 unimolecular), based on a search last updated 2026-06-18.

Is Amycretin FDA-approved?

FDA status: Investigational (Phase 2 oral, Phase 1b subcutaneous).

How does Amycretin work?

Single peptide that activates both the amylin and GLP-1 receptor families.

Single peptide that activates both the amylin and GLP-1 receptor families.

Reference facts

Also known as
NN1213, Amylin/GLP-1 unimolecular
Category
GLP-1 & Metabolic
Mechanism of action
Single peptide that activates both the amylin and GLP-1 receptor families.
Targets
GLP-1R, Amylin receptors
Indications under research or approved
Obesity
Regulatory status (reference entry)
Investigational (Phase 2 oral, Phase 1b subcutaneous)
Half-life
~7 days (subcutaneous formulation)
Sequence notes
Unimolecular dual amylin and GLP-1 receptor agonist; full sequence not publicly disclosed.
Originator / sponsor
Novo Nordisk
First reported
2024

Primary References

Explore research articles about Amycretin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.